Key Highlights
- Clinical launch of MRD test portfolio featuring xM and xM (NeXT Personal® Dx) tests.
- Tumor-naïve and tumor-informed assays designed for early cancer detection and treatment monitoring.
- xM MRD test presented at 2024 ASCO® Annual Meeting shows high sensitivity and specificity.
- Strategic collaboration with Personalis, Inc. to co-commercialize NeXT Personal® Dx for ultra-sensitive MRD testing.
Source: Business Wire
Notable Quote
- “We believe it is important to offer a portfolio of both a rapid, tumor-naïve test and an ultra-sensitive, tumor-informed test so that physicians have optionality in addressing each of their patient’s specific needs. MRD testing is the perfect complement to our comprehensive testing portfolio, as we are now equipping physicians with a proactive solution that provides early-stage cancer insights for their patients that is critical to their care.” — Halla Nimeiri, MD, Chief Development Officer at Tempus
SoHC's Take
The clinical launch of Tempus’ MRD test portfolio represents a significant advancement in precision medicine. By offering both a tumor-naïve and a tumor-informed assay, Tempus is providing physicians with versatile tools to detect residual disease early and monitor treatment responses effectively. The strategic collaboration with Personalis, Inc. further enhances the capability to deliver personalized and highly sensitive MRD testing. These developments underscore Tempus’ commitment to leveraging AI and advanced genomics to improve patient outcomes in oncology.
